April 1, 2020Heart
Acute recurrent pericarditis: from pathophysiology towards new treatment strategy
Why the study?
Recurrences in acute pericarditis are frequent with limited efficacy of corticosteroids or immunosuppressive drugs in refractory cases, prompting review of autoinflammatory/autoimmune mechanisms and IL-1 receptor antagonists.
Do IL-1 receptor antagonists improve outcomes in patients with acute recurrent pericarditis?
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support anakinra in refractory recurrent pericarditis; leaves open need for larger confirmatory trials.
Structured PICO
Do IL-1 receptor antagonists improve outcomes in patients with acute recurrent pericarditis?
P
Population
Patients with acute recurrent pericarditis
I
Intervention
IL-1 receptor antagonists (anakinra, canakinumab, rilonacept)
IL-1 receptor antagonists represent a promising targeted treatment strategy for recurrent pericarditis, addressing the underlying autoinflammatory pathophysiology.
Limitations
- Needs further evaluation in larger prospective clinical trials to replicate initial findings
- Need to assess safety, cost-effectiveness and long-term efficacy
Cite This Study
Cacoub et al. (2020) studied this question.